Odonate Therapeutics, LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03326674
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Odonate Therapeutics, Inc. | Odonate Therapeutics, LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

capecitabine (xeloda) (2 trials)

tesetaxel (4 trials)

Drugs in Phase 2 Trials (3)

atezolizumab (Tecentriq) (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

itraconazole (sporanox) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 7